Literature DB >> 33512584

Spatiotemporal Changes in the Gene Expression Spectrum of the β2 Adrenergic Receptor Signaling Pathway in the Lungs of Rhesus Monkeys.

Zhongmei Zheng1,2,3, Bangrong Cao4, Yu Hu5, Liang Xie6,3, Ling Gu6,3, Fang Shi6,3, Hanmin Liu7,8,9.   

Abstract

OBJECTIVE: β2 adrenergic receptor (ADRB2) agonists mainly participate in regulation of airway function through the ADRB2-G protein-adenylyl cyclase (AC) signaling pathway; however, the key genes associated with this pathway and the spatiotemporal changes in the expression spectrum of some of their subtypes remain unclear, resulting in an insufficient theoretical basis for formulating the dose and method of drug administration for neonates.
METHODS: We performed sampling at different developmental time points in rhesus monkeys, including the embryo stage, neonatal stage, and adolescence. The MiSeq platform was used for sequencing of key genes and some of their subtypes in the ADRB2 signaling pathway in lung tissues, and target gene expression was normalized and calculated according to reads per kilobase million.
RESULTS: At different lung-developmental stages, we observed expression of phenylethanolamine N-methyltransferase (PNMT), ADRB2, AC, AKAP and EPAC subtypes (except AC8, AKAP4/5), and various phosphodiesterase (PDE) subtypes (PDE3, PDE4, PDE7, and PDE8), with persistently high expression of AC6, PDE4B, and AKAP(1/2/8/9/12/13, and EZR) maintained throughout the lung-developmental process, PNMT, ADRB2, AC(4/6), PDE4B, and AKAP(1/2/8/9/12/13, EZR, and MAP2)were highly expressed at the neonatal stage.
CONCLUSION: During normal lung development in rhesus monkeys, key genes associated with ADRB2-G protein-AC signaling and some of their subtypes are almost all expressed at the neonatal stage, suggesting that this signaling pathway plays a role in this developmental stage. Additionally, AC6, PDE4B, and AKAP(1/2/8/9/12/13, and EZR) showed persistently high expression during the entire lung-developmental process, which provides a reference for the development and utilization of key gene subtypes in this pathway.

Entities:  

Keywords:  Gene expression; Rhesus monkeys; Signaling pathway; Β2 adrenergic receptor

Year:  2021        PMID: 33512584      PMCID: PMC7870609          DOI: 10.1007/s00408-021-00420-2

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  40 in total

1.  A-kinase anchoring proteins regulate compartmentalized cAMP signaling in airway smooth muscle.

Authors:  Sarah J Horvat; Deepak A Deshpande; Huandong Yan; Reynold A Panettieri; Juan Codina; Thomas D DuBose; Wenkuan Xin; Thomas C Rich; Raymond B Penn
Journal:  FASEB J       Date:  2012-05-30       Impact factor: 5.191

Review 2.  Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD.

Authors:  Mario Cazzola; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Expert Opin Investig Drugs       Date:  2019-09-01       Impact factor: 6.206

3.  Human airway smooth muscle expresses 7 isoforms of adenylyl cyclase: a dominant role for isoform V.

Authors:  D Xu; C Isaacs; I P Hall; C W Emala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2001-10       Impact factor: 5.464

4.  Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent.

Authors:  Matthias C Hütten; Markus Fehrholz; Franziska M Konrad; Daan Ophelders; Clementine Kleintjes; Barbara Ottensmeier; Owen Brad Spiller; Kirsten Glaser; Boris W Kramer; Steffen Kunzmann
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-10-01       Impact factor: 2.849

5.  Epistasis between phenylethanolamine N-methyltransferase and β2-adrenergic receptor influences extracellular epinephrine level and associates with the susceptibility to allergic asthma.

Authors:  Yang Yie Sio; Sri Anusha Matta; Yu Ting Ng; Fook Tim Chew
Journal:  Clin Exp Allergy       Date:  2020-01-15       Impact factor: 5.018

6.  Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells.

Authors:  Brijeshkumar S Patel; Pavan Prabhala; Brian G Oliver; Alaina J Ammit
Journal:  Am J Respir Cell Mol Biol       Date:  2015-05       Impact factor: 6.914

Review 7.  Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia.

Authors:  Erica W Mandell; Panagiotis Kratimenos; Steven H Abman; Robin H Steinhorn
Journal:  Clin Perinatol       Date:  2019-03-30       Impact factor: 3.430

8.  Effect of Adenylyl Cyclase Type 6 on Localized Production of cAMP by β-2 Adrenoceptors in Human Airway Smooth-Muscle Cells.

Authors:  Shailesh R Agarwal; Chase Fiore; Kathryn Miyashiro; Rennolds S Ostrom; Robert D Harvey
Journal:  J Pharmacol Exp Ther       Date:  2019-05-08       Impact factor: 4.030

Review 9.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Cigarette smoke up-regulates PDE3 and PDE4 to decrease cAMP in airway cells.

Authors:  Haoxiao Zuo; Bing Han; Wilfred J Poppinga; Lennard Ringnalda; Loes E M Kistemaker; Andrew J Halayko; Reinoud Gosens; Viacheslav O Nikolaev; Martina Schmidt
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

View more
  1 in total

1.  LUNG Year in Review: 2021.

Authors:  Peter V Dicpinigaitis
Journal:  Lung       Date:  2022-01-18       Impact factor: 3.777

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.